Assignee
MORPHOTEK INC
US·41 granted patents·11 pending applications·240 citations·filing 2000–2017
Top patents by PatentIndex Score
52 records- 0197US7592426B2Anti-mesothelin antibodiesMORPHOTEK INC·Filed 2006·Granted Sep 22, 2009·38 cites·14 claims
- 0295US9115197B2Anti-mesothelin antibodiesMORPHOTEK INC·Filed 2014·Granted Aug 25, 2015·15 cites·16 claims
- 0395US6808894B1Methods for generating genetically altered antibody producing cell lines with improved antibody characteristicsMORPHOTEK INC·Filed 2000·Granted Oct 26, 2004·43 cites·21 claims
- 0494US7615372B2Antibodies with immune effector activity and that internalize in endosialin-positive cellsMORPHOTEK INC·Filed 2006·Granted Nov 10, 2009·12 cites·12 claims
- 0593US7741450B2Antibodies to GM-CSFMORPHOTEK INC·Filed 2007·Granted Jun 22, 2010·21 cites·6 claims
- 0692US8524237B2Antibodies with immune effector activity and that internalize in endosialin-positive cellsMORPHOTEK INC·Filed 2012·Granted Sep 3, 2013·6 cites·14 claims
- 0789US7807382B2Methods for inhibiting the binding of endosialin to ligandsMORPHOTEK INC·Filed 2008·Granted Oct 5, 2010·11 cites·8 claims
- 0887US6576468B1Methods for obtaining microbe-resistant mammalian cells from hypermutable mammalian cellsMORPHOTEK INC·Filed 2000·Granted Jun 10, 2003·14 cites·18 claims
- 0986US8895704B2High affinity antibodies that neutralize Staphylococcus enterotoxin BMORPHOTEK INC·Filed 2013·Granted Nov 25, 2014·6 cites·6 claims
- 1085US9650440B2Monoclonal antibodies that specifically block biological activity of a tumor antigenMORPHOTEK INC·Filed 2013·Granted May 16, 2017·5 cites·16 claims
- 1185US6737268B1Method for generating genetically altered antigensMORPHOTEK INC·Filed 2000·Granted May 18, 2004·10 cites·10 claims
- 1284US9359428B2High affinity antibodies that neutralize Staphylococcus enterotoxin BMORPHOTEK INC·Filed 2014·Granted Jun 7, 2016·4 cites·4 claims
- 1383US7235643B2Antibodies and methods for generating genetically altered antibodies with high affinityMORPHOTEK INC·Filed 2002·Granted Jun 26, 2007·7 cites·5 claims
- 1482US9868780B2High affinity antibodies that neutralize Staphylococcus enterotoxin BMORPHOTEK INC·Filed 2016·Granted Jan 16, 2018·2 cites·4 claims
- 1582US7671179B2Antibodies and methods for generating genetically altered antibodies with high affinityMORPHOTEK INC·Filed 2007·Granted Mar 2, 2010·3 cites·5 claims
- 1682US7604994B2Genetically altered antibody-producing cell lines with improved antibody characteristicsMORPHOTEK INC·Filed 2004·Granted Oct 20, 2009·5 cites·29 claims
- 1781US6900370B2Method for generating hypermutable plantsMORPHOTEK INC·Filed 2000·Granted May 31, 2005·10 cites·12 claims
- 1880US9234015B2Chlorotoxin polypeptides and conjugates and uses thereofMORPHOTEK INC·Filed 2014·Granted Jan 12, 2016·3 cites·16 claims
- 1979US7223598B2Methods for isolating novel antimicrobial agents from hypermutable mammalian cellsMORPHOTEK INC·Filed 2005·Granted May 29, 2007·2 cites·7 claims
- 2078US7754450B2Methods of generating high-production of antibodies from hybridomas created by in vitro immunizationMORPHOTEK INC·Filed 2003·Granted Jul 13, 2010·5 cites·45 claims
- 2177US8658173B2Anti-mesothelin antibodiesMORPHOTEK INC·Filed 2013·Granted Feb 25, 2014·1 cites·11 claims
- 2277US6982169B2Chemical inhibitors of mismatch repairMORPHOTEK INC·Filed 2001·Granted Jan 3, 2006·4 cites·29 claims
- 2376US9522195B2Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cellsMORPHOTEK INC·Filed 2015·Granted Dec 20, 2016·1 cites·12 claims
- 2475US9139656B2TEM-1 diagnostic antibodiesMORPHOTEK INC·Filed 2013·Granted Sep 22, 2015·2 cites·12 claims
- 2573US9505842B2Methods for inhibiting the binding of endosialin to ligandsMORPHOTEK INC·Filed 2014·Granted Nov 29, 2016·1 cites·5 claims
- 2672US9637526B2Chlorotoxin polypeptides and conjugates and uses thereofMORPHOTEK INC·Filed 2015·Granted May 2, 2017·1 cites·72 claims
- 2772US7638334B2Method for generating engineered cells by homologously recombining segments having increased degeneracyMORPHOTEK INC·Filed 2003·Granted Dec 29, 2009·3 cites·46 claims
- 2869US9603952B2Treatment of metastatic tumorsMORPHOTEK INC·Filed 2015·Granted Mar 28, 2017·1 cites·33 claims
- 2969US2006239910A1Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cellsMORPHOTEK INC·Filed 2006·Application pending·0 cites
- 3068US2015010473A1Diagnosis and treatment of tumorsMORPHOTEK INC·Filed 2014·Application pending·0 cites
- 3164US9422367B2Antigenic GM-CSF peptides and antibodies to GM-CSFMORPHOTEK INC·Filed 2013·Granted Aug 23, 2016·0 cites·20 claims
- 3264US8956832B2Cells expressing anti-GD2 antibodies and methods related theretoMORPHOTEK INC·Filed 2013·Granted Feb 17, 2015·0 cites·4 claims
- 3364US7807416B2Antibodies and methods for generating genetically altered antibodies with enhanced effector functionMORPHOTEK INC·Filed 2008·Granted Oct 5, 2010·0 cites·7 claims
- 3463US10253106B2Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cellsMORPHOTEK INC·Filed 2016·Granted Apr 9, 2019·0 cites·4 claims
- 3563US7332584B2Antibodies that specifically bind PMS2MORPHOTEK INC·Filed 2004·Granted Feb 19, 2008·3 cites·8 claims
- 3663US2010021996A1Genetically Altered Anti-body Producing Cell Lines With Improved Antibody CharacteristicsMORPHOTEK INC·Filed 2009·Application pending·0 cites
- 3762US7939324B2Methods for isolating novel antimicrobial agents from hypermutable mammalian cellsMORPHOTEK INC·Filed 2007·Granted May 10, 2011·0 cites·5 claims
- 3861US10053509B2Methods for inhibiting the binding of endosialin to ligandsMORPHOTEK INC·Filed 2016·Granted Aug 21, 2018·0 cites·2 claims
- 3961US10023632B2Antigenic GM-CSF peptides and antibodies to GM-CSFMORPHOTEK INC·Filed 2016·Granted Jul 17, 2018·0 cites·8 claims
- 4060US10183975B2Chlorotoxin polypeptides and conjugates and uses thereofMORPHOTEK INC·Filed 2017·Granted Jan 22, 2019·0 cites·29 claims
- 4160US2004158886A1Method for generating genetically altered antigensMORPHOTEK INC·Filed 2004·Application pending·0 cites
- 4259US9915660B2Methods for determining prognosis of colorectal cancerMORPHOTEK INC·Filed 2014·Granted Mar 13, 2018·0 cites·14 claims
- 4357US9512223B2Methods for treatment of gastric cancerMORPHOTEK INC·Filed 2013·Granted Dec 6, 2016·1 cites·6 claims
- 4457US2005232919A1Monoclonal antibodies that specifically block biological activity of a tumor antigenMORPHOTEK INC·Filed 2005·Application pending·0 cites
- 4556US2008124744A1Antibodies That Specifically Bind PMS2MORPHOTEK INC·Filed 2007·Application pending·0 cites
- 4656US2004115695A1Methods for generating enhanced antibody producing cell lines with improved growth characteristicsMORPHOTEK INC·Filed 2003·Application pending·0 cites
- 4752US9771429B2TEM-1 diagnostic antibodiesMORPHOTEK INC·Filed 2015·Granted Sep 26, 2017·0 cites·13 claims
- 4849US2016311921A1Methods for treatment of ovarian cancerMORPHOTEK INC·Filed 2014·Application pending·0 cites
- 4945US2008131427A1Whole Genome Evolution Technology Applied To Improve Protein And Antibody Yields By CellsMORPHOTEK INC·Filed 2007·Application pending·0 cites
- 5037US2010260769A1Endosialin binding moleculesMORPHOTEK INC·Filed 2010·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MORPHOTEK INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →